Document is current
Any future updates will be listed below
-
Authors
Mesropyan, Narine https://orcid.org/0000-0002-5871-3965
Chang, Johannes
Lutz, Philipp
Kaiser, Felix
Weber, Oliver M.
Katemann, Christoph
Dell, Tatjana
Kravchenko, Dmitrij
Yueksel, Can
Kuetting, Daniel
Pieper, Claus C.
Luetkens, Julian A.
Isaak, Alexander
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (493623632)
- License Information
-
More Information
Article History
Received: 1 September 2025
Revised: 29 October 2025
Accepted: 24 November 2025
First Online: 20 December 2025
Compliance with ethical standards
:
: The scientific guarantor of this publication is Narine Mesropyan.
: The authors affiliated with Philips Healthcare (C.K. and O.M.W.), who supported the development of the T1ρ mapping sequence, had no role in the study design, data acquisition, analysis, or interpretation of the results. The remaining authors declare no conflicts of interest related to this study.
: One of the authors has significant statistical expertise.
: Only if the study is on human subjects: written informed consent was obtained from all subjects (patients) in this study.
: Institutional Review Board approval was obtained (no. 155/23-EP).
: A subset of patients ( n = 27/112) included in the present study was also part of a recently published cohort ( ). This overlap is due to partially joint recruitment during a partially overlapping study period. However, this had no impact on the current study results, as the previous study focused on the evaluation of a newly developed Dixon-based water T1 mapping sequence for fat corrected assessment of hepatic fibrosis. The present study represents the clinical translation of earlier preclinical work in animal models of SLD ( ), which investigated the diagnostic value of T1ρ mapping for assessing liver fibrosis in CLD, including SLD.
:
